Table 1.
Selected cervical cancer patient demographic, clinical and treatment characteristics, cervical cancer prognosis study, Kampala, Uganda, 2013–2015.
| Characteristic | HIV-negative, # (%) (n = 96) |
HIV-positive, # (%) (n = 53) |
|---|---|---|
| Median age (IQR), years | 54 (47–62) | 44 (39–48) |
| Highest education completed | ||
| - None | 25 (34) | 8 (19) |
| - Primary | 42 (57) | 22 (52) |
| - Secondary or greater | 7 (9) | 12 (29) |
| - Unknown* | 22 | 11 |
| Tobacco use | ||
| - Lifelong non-smoker | 90 (94) | 51 (98) |
| - Current smoker | 1 (1) | 0 (0) |
| - Former smoker | 5 (5) | 1 (2) |
| - Unknown* | 0 | 1 |
| Live births | ||
| - 0 | 1 (1) | 0 (0) |
| - 1–3 | 12 (13) | 20 (38) |
| - 4–7 | 33 (34) | 24 (45) |
| - 8+ | 50 (52) | 9 (17) |
| Median BMI (IQR) | 23 (20–27) | 23 (19–25) |
| ECOG performance status | ||
| - 0 | 2 (2) | 0 (0) |
| - 1 | 80 (84) | 48 (91) |
| - 2 | 8 (8) | 4 (7) |
| - 3 | 6 (6) | 1 (2) |
| Transport cost to UCI (USh) | ||
| - ≤20,000 | 50 (52) | 42 (79) |
| - 21,000–40,000 | 26 (27) | 8 (15) |
| - 41,000–60,000 | 16 (17) | 3 (6) |
| - >60,000 | 4 (4) | 0 (0) |
| FIGO stage | ||
| - I | 12 (12) | 10 (19) |
| - II | 47 (49) | 26 (49) |
| - III | 33 (35) | 15 (28) |
| - IV | 4 (4) | 2 (4) |
| Tumor histology | ||
| - Squamous | 95 (95) | 48 (90) |
| - Adenocarcinoma | 4 (4) | 4 (8) |
| - Other | 1 (1) | 1 (2) |
| Tumor grade | ||
| - Well differentiated | 1 (1) | 5 (10) |
| - Moderately differentiated | 22 (23) | 13 (25) |
| - Poorly/undifferentiated | 71 (76) | 33 (65) |
| - Unknown | 2 | 2 |
| Type of initial treatment | ||
| - Chemoradiation | 21 (25) | 10 (21) |
| - Chemotherapy only | 1 (1) | 1 (2) |
| - Radiation therapy only | 40 (49) | 27 (56) |
| - Surgery only | 0 (0) | 1 (2) |
| - Surgery + adjuvant treatmenta | 0 (0) | 2 (4) |
| - No treatment | 21 (25) | 7 (15) |
| - Unknown* | 13 | 5 |
| Total radiation therapy received | ||
| - <73.75 Gy | 25 (42) | 15 (43) |
| - ≥73.75 Gy | 34 (58) | 20 (57) |
| - Unknown* | 2 | 2 |
| - Did not receive upfront radiotherapy | 35 | 16 |
| Median baseline hemoglobinb (IQR), g/dL | 12.0 (9.9–12.9) | 10.5 (8.6–12.5) |
| Median CD4 at enrollment, (IQR), cells/mm3 | 926 (639–1045) | 373 (300–502) |
| Enrolled in HIV care services at enrollment | – | |
| - Yes | – | 45 (88) |
| - No | – | 6 (12) |
| - Unknown* | 2 | |
| Duration of HIV infection | ||
| - <1 year | – | 8 (16) |
| − 1–5 years | – | 17 (33) |
| - >5 years | – | 26 (51) |
| - Unknown* | – | 2 |
| HIV plasma RNA level at enrollment | ||
| - <500 copies/mL | – | 41 (77) |
| - ≥500 copies/mL | – | 12 (23) |
| HAART use at enrollment | ||
| - No | – | 12 (23) |
| - Yes | – | 41 (77) |
Abbreviations: IQR = interquartile range; UCI = Uganda Cancer Institute; USh = Ugandan shillings; ECOG = Eastern Cooperative Oncology Group.
*
Missing data are shown as separate category for categorical variables, but percentages were calculated among non-missing data only.
a
1 patient received radiation therapy; 1 patient received concurrent chemoradiation.
b
Baseline hemoglobin was not available for 34 (35%) of HIV-negative and 16 (30%) of HIV-positive patients.